Department of Pathology Laboratories

Notification Date: March 18th, 2025 Effective Date: March 18th, 2025

Cystic Fibrosis (CFTR) Carrier Screening and Diagnostic Testing – Update to Ordering Process


Orderable: Cystic Fibrosis (CFTR) [LAB1233901]

Beginning March 18th, 2025, the Molecular Diagnostics Laboratory will amend the order for Cystic Fibrosis testing to require an indication for testing – "Prenatal Screening" or "Diagnostic." The "Prenatal Screening" option should be selected when screening for Cystic Fibrosis carrier status during or prior to pregnancy. The "Diagnostic" option should be selected when there is a clinical concern that the patient could have a diagnosis of Cystic Fibrosis. These options will be available in the order screen in EPIC and must be selected to complete the order. This change will not impact the assay results; however, result interpretations specific with the order indication will be reported.

This new order will replace the stand-alone Cystic Fibrosis (CFTR) Carrier Screening and Cystic Fibrosis (CFTR) Diagnosis orderables.

Specimen requirements and turnaround time will remain the same.

Order Prior to March 18th, 2025	New Order
Cystic Fibrosis (CFTR) Carrier Screening	
(LAB1230174)	Cystic Fibrosis (CFTR)
Cystic Fibrosis (CFTR) Diagnosis	(LAB1233901)
(LAB1230175)	



For questions, please contact Pathology Client Services at (804) 828-7284 or the Molecular Diagnostics Laboratory at (804) 828-9564.